Journal Mobile Options
Table of Contents
Vol. 24, No. 2, 2007
Issue release date: July 2007
Dement Geriatr Cogn Disord 2007;24:98–103

Cognitive Impairment in Alzheimer’s Disease Is Modified by APOE Genotype

van der Vlies A.E. · Pijnenburg Y.A.L. · Koene T. · Klein M. · Kok A. · Scheltens P. · van der Flier W.M.
Departments of aNeurology and Alzheimer Center, bMedical Psychology and cClinical Chemistry, VU University Medical Center, Amsterdam, The Netherlands

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Aim: We examined whether impairment in specific cognitive domains in Alzheimer’s disease (AD) differed according to APOE genotype and age at onset. Methods: Cognitive functions of 229 consecutive AD patients were assessed using Visual Association Test (VAT), Memory Impairment Screen+ (MIS+), VAT object naming, fluency test and Trail Making Test (TMT). Dementia severity was assessed using MMSE. ANOVAs were performed with APOE genotype and age at onset as independent variables and sex, education and MMSE as covariates. Results: 28% of patients were APOE ε4-negative, 58% heterozygous and 14% homozygous. A significant association between APOE genotype and VAT and MIS+ was found when correcting for sex and education. An interaction effect between APOE genotype and age at onset on VAT and VAT object naming was found, with young carriers performing worse than young noncarriers. By contrast, when additionally correcting for MMSE, a significant association between APOE genotype and VAT object naming, TMT-A and TMT-B was found, with noncarriers performing worse than carriers. Conclusion: Memory was more impaired among APOE ε4 carriers than among noncarriers. By contrast, naming, executive functions and mental speed were more impaired among APOE ε4 noncarriers. This suggests that the APOE genotype modifies the clinical phenotype in terms of cognitive impairment in AD.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 1984;34:939–944.
  2. Galton CJ, Patterson K, Xuereb JH, Hodges JR: Atypical and typical presentations of Alzheimer’s disease: a clinical, neuropsychological, neuroimaging and pathological study of 13 cases. Brain 2000;123:484–498.
  3. Seltzer B, Sherwin I: A comparison of clinical features in early- and late-onset primary degenerative dementia: one entity or two? Arch Neurol 1983;40:143–146.
  4. Sevush S, Leve N, Brickman A: Age at disease onset and pattern of cognitive impairment in probable Alzheimer’s disease. J Neuropsychiatry Clin Neurosci 1993;5:66–72.
  5. Greicius MD, Geschwind MD, Miller BL: Presenile dementia syndromes: an update on taxonomy and diagnosis. J Neurol Neurosurg Psychiatry 2002;72:691–700.
  6. Lehtovirta M, Soininen H, Helisalmi S, Mannermaa A, Helkala EL, Hartikainen P, Hanninen T, Ryynanen M, Riekkinen PJ: Clinical and neuropsychological characteristics in familial and sporadic Alzheimer’s disease: relation to apolipoprotein E polymorphism. Neurology 1996;46:413–419.
  7. Suribhatla S, Baillon S, Dennis M, Marudkar M, Muhammad S, Munro D, Spreadbury C, Lindesay J: Neuropsychological performance in early and late onset Alzheimer’s disease: comparisons in a memory clinic population. Int J Geriatr Psychiatry 2004;19:1140–1147.
  8. Slooter AJC, Cruts M, Kalmijn S, Hofman A, Breteler MMB, Van Broeckhoven C, van Duijn CM: Risk estimates of dementia by apolipoprotein E genotypes from a population-based incidence study: the Rotterdam Study. Arch Neurol 1998;55:964–968.
  9. Strittmatter WJ, Roses AD: Apolipoprotein E and Alzheimer disease. Proc Natl Acad Sci USA 1995;92:4725–4727.
  10. Kuusisto J, Koivisto K, Kervinen K, Mykkanen L, Helkala EL, Vanhanen M, Hanninen T, Pyorala K, Kesaniemi YA, Riekkinen P, Laakso M: Association of apolipoprotein E phenotypes with late onset Alzheimer’s disease: population-based study. BMJ 1994;309:636–638.
  11. Petersen RC, Thomas RG, Grundman M, Bennett D, Doody R, Ferris S, Galasko D, Jin S, Kaye J, Levey A, Pfeiffer E, Sano M, van Dyck CH, Thal LJ: Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 2005;352:2379–2388.
  12. Kleiman T, Zdanys K, Black B, Rightmer T, Grey M, Garman K, Macavoy M, Gelernter J, van Dyck C: Apolipoprotein E epsilon4 allele is unrelated to cognitive or functional decline in Alzheimer’s disease: retrospective and prospective analysis. Dement Geriatr Cogn Disord 2006;22:73–82.
  13. Poirier J, Davignon J, Bouthillier D, Kogan S, Bertrand P, Gauthier S: Apolipoprotein E polymorphism and Alzheimer’s disease. Lancet 1993;342:697–699.
  14. Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS, Roses AD: Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci USA 1993;90:1977–1981.
  15. Schott JM, Ridha BH, Crutch SJ, Healy DG, Uphill JB, Warrington EK, Rossor MN, Fox NC: Apolipoprotein E genotype modifies the phenotype of Alzheimer disease. Arch Neurol 2006;63:155–156.
  16. Marra C, Bizzarro A, Daniele A, De Luca L, Ferraccioli M, Valenza A, Brahe C, Tiziano FD, Gainotti G, Masullo C: Apolipoprotein E epsilon4 allele differently affects the patterns of neuropsychological presentation in early- and late-onset Alzheimer’s disease patients. Dement Geriatr Cogn Disord 2004;18:125–131.
  17. van der Flier WM, Schoonenboom SNM, Pijnenburg YAL, Fox NC, Scheltens P: The effect of APOE genotype on clinical phenotype in Alzheimer disease. Neurology 2006;67:526–527.
  18. Verhage F: Intelligence and Age: Study with Dutch People Aged 12–77 (in Dutch). Assen, Van Gorcum, 1964.
  19. Folstein MF, Folstein SE, McHugh PR: ‘Mini-mental state’: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189–198.
  20. Lindeboom J, Schmand B, Tulner L, Walstra G, Jonker C: Visual association test to detect early dementia of the Alzheimer type. J Neurol Neurosurg Psychiatry 2002;73:126–133.
  21. Buschke H, Kuslansky G, Katz M, Stewart WF, Sliwinski MJ, Eckholdt HM, Lipton RB: Screening for dementia with the memory impairment screen. Neurology 1999;52:231–238.
  22. Reitan RM: Validity of the Trail Making Test as an indicator of organic brain damage. Percept Mot Skills 1958;8:271–276.

    External Resources

  23. Lind J, Larsson A, Persson J, Ingvar M, Nilsson LG, Backman L, Adolfsson R, Cruts M, Sleegers K, Van Broeckhoven C, Nyberg L: Reduced hippocampal volume in non-demented carriers of the apolipoprotein E epsilon4: relation to chronological age and recognition memory. Neurosci Lett 2006;396:23–27.
  24. den Heijer T, Oudkerk M, Launer LJ, van Duijn CM, Hofman A, Breteler MMB: Hippocampal, amygdalar, and global brain atrophy in different apolipoprotein E genotypes. Neurology 2002;59:746–748.
  25. Moffat SD, Szekely CA, Zonderman AB, Kabani NJ, Resnick SM: Longitudinal change in hippocampal volume as a function of apolipoprotein E genotype. Neurology 2000;55:134–136.
  26. Hashimoto M, Yasuda M, Tanimukai S, Matsui M, Hirono N, Kazui H, Mori E: Apolipoprotein E epsilon 4 and the pattern of regional brain atrophy in Alzheimer’s disease. Neurology 2001;57:1461–1466.
  27. Frisoni GB, Govoni S, Geroldi C, Bianchetti A, Calabresi L, Franceschini G, Trabucchi M: Gene dose of the epsilon 4 allele of apolipoprotein E and disease progression in sporadic late-onset Alzheimer’s disease. Ann Neurol 1995;37:596–604.
  28. Stern Y, Brandt J, Albert M, Jacobs DM, Liu XH, Bell K, Marder K, Sano M, Albert S, Del-Castillo Castenada C, Bylsma F, Tycko B, Mayeux R: The absence of an apolipoprotein epsilon4 allele is associated with a more aggressive form of Alzheimer’s disease. Ann Neurol 1997;41:615–620.
  29. Bretsky P, Guralnik JM, Launer L, Albert M, Seeman TE: The role of APOE-epsilon4 in longitudinal cognitive decline: MacArthur Studies of Successful Aging. Neurology 2003;60:1077–1081.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50